Efficacy News and Research

RSS

FDA approves Combunox tablets for the short-term treatment of acute, moderate to severe pain

Forest Laboratories have announced that Combunox (Oxycodone HCl and Ibuprofen) Tablets (CII), the first and only fixed-dose combination of the opioid oxycodone HCl (5 mg) and the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen (400 mg), was approved by the U.S. Food and Drug Administration (FDA) for the short-term management of acute, moderate to severe pain.

29 Nov 2004

U.S. pharmacists not opposed to importing drugs to lower patients' costs

Many community pharmacists are not opposed to importing drugs to lower patients' costs as long as those drugs are channeled through U.S. pharmacies to ensure safety and efficacy, according to a study by pharmacists at the University of Illinois at Chicago and the University of Michigan.

24 Nov 2004

Stem cells derived from umbilical cords are a viable and effective transplant source for thousands of leukemia patients

A new study published in the New England Journal of Medicine confirms that stem cells derived from the umbilical cords of newborn babies are a viable and effective transplant source for thousands of leukemia patients who have no other treatment option.

24 Nov 2004

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

Low-dose antioxidant supplementation may reduce the risk of cancer among men, but not in women

According to the article, antioxidants including beta carotene, ascorbic acid, vitamin E, selenium, and zinc may prevent some of the harmful effects caused by free radicals – reactive molecules produced by metabolism in the body.

23 Nov 2004

Hetero Drugs withdraws antiretrovirals

Following an inspection by the World Health Organization (WHO), generic manufacturer Hetero Drugs Limited, in Hyderbad, India, is withdrawing six antiretrovirals from the WHO prequalification list in order to review data on their bioequivalence.

20 Nov 2004

AstraZeneca reconfirms the safety of Crestor

In the case of Crestor (rosuvastatin calcium), the application for approval was the most extensive ever for a statin involving more than 12,000 patients, and was unanimously recommended for approval by the FDA's advisory board in July of 2003.

20 Nov 2004

Capsules may be effective in treating bipolar disorder

University of North Carolina at Chapel Hill researchers have announced study results finding that a formulation of three-beaded extended-release carbamazepine capsules (ERC-CBZ) was effective, safe and tolerable in the treatment of bipolar I disorder

19 Nov 2004

FDA Vioxx fiasco raises questions about AIDS drug approvals for developing world

AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.

19 Nov 2004

Prolonged abstinence, no visual problems in patients taking GVG for meth/cocaine abuse

A second, small clinical trial of a proposed addiction treatment led by investigators at NYU School of Medicine and the U.S. Department of Energy's Brookhaven National Laboratory has produced favorable results in the treatment of long-term addiction to methamphetamine and/or cocaine, with no visual side effects in any of the 30 patients enrolled.

18 Nov 2004

Biotoxin from puffer fish may provide treatment for opioid withdrawal

On November 10, 2004 investigators involved in a Phase IIa clinical trial of the novel biotoxin Tetrodotoxin (TTX) for the treatment of opioid withdrawal enrolled their first participants.

18 Nov 2004

Low-cost antibiotic co-trimoxazole should be given to all children with HIV in developing countries

Results of a randomised trial in this week’s issue of THE LANCET highlight how the low-cost antibiotic co-trimoxazole should be given to all children with HIV in developing countries to help reduce illness and death from opportunistic infections such as pneumonia.

18 Nov 2004

Vasogen announces full patient enrollment in its trial of Celacade in peripheral arterial disease

Vasogen today announced that it has reached full enrollment in its 500-patient pivotal phase III SIMPADICO trial of Celacade (immune modulation therapy) for the treatment of peripheral arterial disease (PAD).

16 Nov 2004

Acetaminophen shows positive cardioprotective effects In heart attack, arrhythmia

Long an under-studied yet widely-used over-the-counter medication, acetaminophen over the last few years is becoming recognized for a range of potential therapeutic uses beyond headache and pain.

16 Nov 2004

Vaccine against human papillomavirus infection could reduce the global incidence of cervical cancer

A randomised trial in this week’s issue of THE LANCET shows how a vaccine against human papillomavirus (HPV) infection could potentially reduce the global incidence of cervical cancer.

14 Nov 2004

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Directed Against R1 and R2 Components of Ribonucleotide Reductase."

10 Nov 2004

Abbott's investigational anti-interleukin-12 fully human monoclonal antibody in Crohn's disease study

Results of a Phase II study of Abbott's ABT-874, a fully human anti-interleukin-12 (IL-12) monoclonal antibody, will appear tomorrow in the New England Journal of Medicine citing treatment with ABT-874 shows differences in response and remission in patients with active Crohn's disease compared to placebo, in one arm of the study.

10 Nov 2004

A new medication has dramatically reduced mortality among African-American patients suffering from heart disease

A new medication has dramatically reduced mortality among African-American patients suffering from heart disease, according to results of a study including UT Southwestern Medical Center at Dallas researchers.

9 Nov 2004

New studies demonstrate efficacy of novel Lipoxin analog in laboratory models of Crohn's disease

Berlex announced today that new laboratory results demonstrate that its modified version of the naturally occurring lipoxin molecule exerts potent anti-inflammatory and immunomodulatory effects in Crohn's disease in vivo models and may provide a promising new oral treatment.

9 Nov 2004

Zetia co-administered with Fenofibrate significantly reduced LDL ("bad") cholesterol in mixed hyperlipidemia patients

Results from a new study showed that coadministration of Zetia (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C) and apo B1 in patients with mixed hyperlipidemia and high LDL cholesterol when compared to fenofibrate alone.

9 Nov 2004

Efficacy News and Research

FDA approves Combunox tablets for the short-term treatment of acute, moderate to severe pain

U.S. pharmacists not opposed to importing drugs to lower patients' costs

Stem cells derived from umbilical cords are a viable and effective transplant source for thousands of leukemia patients

FDA approval of Tysabri, for the treatment of multiple sclerosis

Low-dose antioxidant supplementation may reduce the risk of cancer among men, but not in women

Hetero Drugs withdraws antiretrovirals

AstraZeneca reconfirms the safety of Crestor

Capsules may be effective in treating bipolar disorder

FDA Vioxx fiasco raises questions about AIDS drug approvals for developing world

Prolonged abstinence, no visual problems in patients taking GVG for meth/cocaine abuse

Biotoxin from puffer fish may provide treatment for opioid withdrawal

Low-cost antibiotic co-trimoxazole should be given to all children with HIV in developing countries

Vasogen announces full patient enrollment in its trial of Celacade in peripheral arterial disease

Acetaminophen shows positive cardioprotective effects In heart attack, arrhythmia

Vaccine against human papillomavirus infection could reduce the global incidence of cervical cancer

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Abbott's investigational anti-interleukin-12 fully human monoclonal antibody in Crohn's disease study

A new medication has dramatically reduced mortality among African-American patients suffering from heart disease

New studies demonstrate efficacy of novel Lipoxin analog in laboratory models of Crohn's disease

Zetia co-administered with Fenofibrate significantly reduced LDL ("bad") cholesterol in mixed hyperlipidemia patients

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News